Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 13/20 | 0.58 |
| ▸ | ABL1 | P00519 | 7/20 | 0.58 |
| ▸ | ABL2 | P42684 | 2/20 | 0.58 |
| ▸ | TTBK1 | Q5TCY1 | 1/20 | 0.55 |
| ▸ | TTBK2 | Q6IQ55 | 1/20 | 0.55 |
| ▸ | BRAF | P15056 | 6/20 | 0.55 |
| ▸ | TNNI3K | Q59H18 | 6/20 | 0.55 |
| ▸ | SRC | P12931 | 5/20 | 0.53 |
| ▸ | CDK1 | P06493 | 4/20 | 0.53 |
| ▸ | PRKCA | P17252 | 4/20 | 0.52 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.52 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9928278 | 0.88 | EGFR (0.58) | EGFRABL1ABL2TTBK1TTBK2 | |
| SCHEMBL7492980 | 0.85 | EGFR (0.60) | EGFRABL1ABL2TTBK1TTBK2 | |
| SCHEMBL4740892 | 0.84 | EGFR (0.65) | EGFRABL1ABL2TTBK1TTBK2 | |
| SCHEMBL9928273 | 0.83 | EGFR (0.52) | EGFRBRAFTNNI3KPDGFRB | |
| SCHEMBL9896825 | 0.82 | JAK3 (0.68) | EGFRABL1ABL2 | |
| SCHEMBL9928274 | 0.82 | BRAF (0.52) | EGFRABL1ABL2BRAFTNNI3K | |
| Hydrochloric Acid SCHEMBL9896822 | 0.82 | JAK3 (0.67) | EGFRABL1ABL2 | |
| SCHEMBL12655345 | 0.81 | TTBK1 (0.55) | EGFRABL1ABL2TTBK1TTBK2 | |
| SCHEMBL9928282 | 0.80 | EGFR (0.53) | EGFRABL1ABL2TTBK1TTBK2 | |
| SCHEMBL9903999 | 0.79 | EGFR (0.64) | EGFRABL1ABL2TTBK1TTBK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149902-A1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVE | UBE INDUSTRIES, LTD. (JP) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149902-A1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVE | ERBB2, EGFR, FGFR1 | EGFR 2/4885ABL1 6/4885ABL2 75/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.